Ian Figueroa
General Practice · Kissimmee, FLNPI 1841446911
Payments from drug & device makers
Across 116 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$798
- Lilly USA, LLC$187
- Boehringer Ingelheim$183
- Exact Sciences$176
- Bayer$155
- GSK$150
- plus $804 from 16 others
What the payments were for
- Food & beverage$2,452100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $798 |
| Lilly USA, LLC | 10 | $187 |
| Boehringer Ingelheim | 6 | $183 |
| Exact Sciences | 4 | $176 |
| Bayer | 7 | $155 |
| GSK | 10 | $150 |
| Novartis | 8 | $138 |
| Novo Nordisk | 6 | $109 |
| Merck | 5 | $79 |
| Pfizer | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Johnson & Johnson | 3 | $47 |
| Scilex Pharmaceuticals Inc. | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $46 |
| Amgen | 2 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Renalytix AI, Inc. | 1 | $24 |
| AbbVie | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$243
- Cologuard Collection Kit$125
- JARDIANCE$112
- BREZTRI$110
How this compares
$2,452 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $42,843 |
| EliquisApixaban | 37 | $42,834 |
| FarxigaDapagliflozin Propanediol | 20 | $25,809 |
| JanuviaSitagliptin Phosphate | 12 | $15,208 |
| JardianceEmpagliflozin | 12 | $15,183 |
| LinzessLinaclotide | 11 | $9,926 |
| LantusInsulin Glargine,hum.Rec.Anlog | 14 | $3,149 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,775 |
| Atorvastatin Calcium | 217 | $2,049 |
| Gabapentin | 148 | $1,836 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,498 |
| SynthroidLevothyroxine Sodium | 12 | $1,280 |
| Rosuvastatin Calcium | 129 | $1,219 |
| Losartan Potassium | 130 | $1,211 |
| Glipizide | 49 | $1,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $109 | $42,84322 claims |
| PfizerEliquis | $64 | $42,83437 claims |
| AstraZenecaFarxiga | $798 | $25,80920 claims |
| MerckJanuvia | $79 | $15,20812 claims |
| Boehringer IngelheimJardiance | $183 | $15,18312 claims |
| AbbVieLinzess, Synthroid | $15 | $11,20723 claims |
| Sanofi-aventis U.S. LLCLantus | $24 | $3,14914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.
Other general practice in Kissimmee
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.